Blockchain Press Releases
Flow Cytometry Market worth $7.0 billion | MarketsandMarkets
CHICAGO, Aug. 9, 2023 /PRNewswire/ — In the near future, the flow cytometry industry is poised to undergo remarkable advancements, driven by ongoing innovations in technology and its widening applications across various fields. With the integration of artificial intelligence and machine learning, data analysis and interpretation will become more efficient and accurate, enabling researchers and clinicians to gain deeper insights from complex cellular data. The miniaturization of flow cytometry instruments will lead to portable and point-of-care devices, revolutionizing diagnostics and personalized medicine. Additionally, the incorporation of multi-parameter analysis and higher-throughput capabilities will enhance the speed and comprehensiveness of cellular profiling. As the industry continues to evolve, collaborations between academia, industry, and healthcare will play a pivotal role in shaping the future of flow cytometry, unlocking its potential to uncover novel discoveries and improve patient outcomes.
Flow Cytometry Market in terms of revenue was estimated to be worth $4.7 billion in 2023 and is poised to reach $7.0 billion by 2028, growing at a CAGR of 8.3% from 2023 to 2028 according to a new report by MarketsandMarkets™.
The growth of this market is driven by the increasing prevalence of chronic diseases and increasing funding for research. Moreover, the launch of novel products in the market by key market players and increased use of flow cytometry in clinical research & diagnostics, such as HIV/AIDS Monitoring, organ transplantation, and cancer diagnostics, are some of the elements propelling the growth of the market.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65374584
Browse in-depth TOC on “Flow Cytometry Market”
477 – Tables
47 – Figures
416 – Pages
Flow Cytometry Market Scope:
|
Report Coverage |
Details |
|
Market Revenue in 2023 |
$4.7 billion |
|
Estimated Value by 2028 |
$7.0 billion |
|
Growth Rate |
Poised to grow at a CAGR of 8.3% |
|
Market Size Available for |
2021–2028 |
|
Forecast Period |
2023–2028 |
|
Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Technology, Product & Service, Application & End User |
|
Geographies Covered |
North America, Europe, Asia Pacific, Latin America (LATAM), and Middle East and Africa (MEA) |
|
Report Highlights |
Updated financial information / product portfolio of players |
|
Key Market Opportunities |
Public-private funding initiatives in stem cell research |
|
Key Market Drivers |
Technological advancements in flow cytometry instruments |
The Reagents & consumables segment accounted for the largest share of the product & service segment in the flow cytometry market in 2022.
Based on products & services, the flow cytometry market is segmented into software, services, reagents & consumables, instruments, and accessories. Reagents & consumables accounted for the largest share of the flow cytometry market in 2022. The factors attributable to the growth, development of high-quality reagents, increased research activities, and launch of application-specific cytometry reagents.
The Research application segment accounted for the largest share of the application segment in the flow cytometry market in 2022.
Based on applications, the flow cytometry market is segmented into clinical, research and industrial applications. In 2022, the research applications segment accounted for the dominant share in the global flow cytometry market. The dominance of the market is attributable to various factors, such as increased research activities & funding and a rise in industrial & academic collaboration. The clinical applications segment is likely to grow at a significant CAGR owing to the increased adoption of flow cytometry in clinical applications.
North America dominated the flow cytometry market in 2022.
Based on region, the flow cytometry market is segmented into North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa. In 2022, North America dominated the market, followed by Europe. The presence of key market players in the region and increasing public-private initiatives for research activities are key factors supporting the growth of the North American flow cytometry market. The Asia Pacific market is projected to grow at the highest CAGR during the forecast period. The high prevalence of HIV/AIDS & cancer and rising treatment options for target diseases (cancer and immunological disorders) are driving the market growth. Further factors like rising government funding and the strong presence of key players in the region are some of the factors anticipated to contribute to the flow cytometry market growth in the Asia Pacific.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=65374584
Flow Cytometry Market Dynamics:
Drivers:
- Rising incidence of HIV/AIDS and cancer
- Wide applications in research for drug discovery & development
- Use of flow cytometry in regenerative medicine
- Growing public-private initiatives in immunology and immuno-oncology research
- Technological advancements in flow cytometry instruments
Restraints:
- High product pricing
Opportunities:
- High growth potential in emerging economies
- Rising focus on stem cell research
- Uptake of recombinant DNA technology for antibody production
Challenges:
- Complexities related to reagent development
- Shortage of skilled professionals
Key Market Players:
Key players in the flow cytometry market include BD (US), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), Sony Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Miltenyi Biotec (Germany), Enzo Biochem, Inc. (US), Sysmex Corporation (Japan), bioMérieux (France), Cytonome/ST, LLC (US), Sartorius AG (Germany), Cytek Biosciences (US), Union Biometrica, Inc. (US), Luminex Corporation (Italy), Apogee Flow Systems Ltd. (UK), Stratedigm, Inc. (US), NanoCellect Biomedical, Inc. (US), On-chip Biotechnologies, Co., Ltd. (Japan), (US), Nexcelom Biosciences LLC. (US), BennuBio Inc. (US), Orflo Technologies (US), Bay Biosciences Co., Ltd. (Japan), BioLegend, Inc. (US), and CytoBuoy B.V (Netherlands).
Recent Developments:
- In June 2023, BD launched The BD FACSDuet Premium Sample Preparation System to automate sample preparation in clinical flow cytometry diagnostics.
- In May 2023, Sysmex launched Clinical Flow Cytometry System Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products in Japan.
- In June 2022, BD (US) launched BD FACSDiscover S8 Cell Sorter with high-speed imaging technology that sorts cells based on visual characteristics.
- In March 2022, Beckman Coulter, Inc. (US) launched a fully automated sample preparation system (SPS) CellMek SPS, which offers on-demand processing for many sample types to help laboratories expand their capabilities.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=65374584
Flow Cytometry Market Advantages:
- Multiparameter Analysis: Flow cytometry enables simultaneous analysis of multiple cellular parameters (e.g., size, shape, markers), offering a comprehensive view of complex cell populations and their interactions.
- Single-Cell Resolution: The technology provides insights into individual cells, allowing researchers to study heterogeneity, identify rare cell populations, and understand cellular behavior at a granular level.
- High Throughput: Flow cytometers can analyze thousands of cells per second, facilitating rapid data acquisition and significantly reducing experiment duration.
- Automation and Reproducibility: Integration of automation and robotics ensures consistent and reproducible results, minimizing experimental variations and human errors.
- Cell Sorting: Flow cytometers equipped with cell sorting capabilities enable isolation of specific cell subsets for downstream analysis, transplantation, or further experimentation.
- Functional Analysis: Flow cytometry can assess cellular functions, such as viability, proliferation, apoptosis, and cell cycle progression, providing insights into cell health and behavior.
- Immunophenotyping: Valuable in immunology research, flow cytometry helps characterize immune cell populations, aiding in the understanding of immune responses, diseases, and therapies.
- Drug Discovery: Flow cytometry plays a pivotal role in drug development by assessing drug effects on cells, identifying potential drug candidates, and evaluating drug toxicity.
- Cancer Research: It aids in cancer diagnostics and research by detecting cancer cells, characterizing tumor heterogeneity, and evaluating treatment responses.
- Personalized Medicine: Flow cytometry contributes to personalized medicine by enabling tailored treatments based on individual patient profiles and disease characteristics.
- Advanced Data Analysis: Integration with AI and machine learning enhances data interpretation, uncovering complex patterns and relationships within datasets.
- Portable Systems: Miniaturization of instruments results in portable flow cytometry devices suitable for point-of-care diagnostics, field research, and resource-limited settings.
- Clinical Applications: It’s used in clinical laboratories for diagnosing immunological disorders, monitoring disease progression, and assessing treatment efficacy.
- Research Versatility: Flow cytometry finds applications in various fields, including immunology, hematology, microbiology, neuroscience, stem cell research, and more.
- Collaborative Potential: The technology encourages collaboration between researchers, clinicians, and industries, fostering cross-disciplinary advancements.
These pointers highlight the multifaceted advantages of flow cytometry, making it an indispensable tool in scientific research, clinical diagnostics, and healthcare innovation.
Related Reports:
Cell Analysis Market – Global Forecasts to 2028
Single Cell Analysis Market – Global Forecasts to 2028
Stem Cell Assay Market – Global Forecasts to 2027
Esoteric Testing Market – Global Forecasts to 2026
Sepsis Diagnostics Market – Global Forecasts to 2026
About MarketsandMarkets™:
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/flow-cytometry-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/flow-cytometry.asp
Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/flow-cytometry-market-worth-7-0-billion–marketsandmarkets-301896791.html
“The Game is On”
TAIPEI, Jan. 23, 2025 /PRNewswire/ — TiltPlay, a gaming platform offering fast-paced and engaging casual games, is proud to announce its official launch on the Soneium ecosystem. This launch positions TiltPlay as dynamic, skill-focused gaming experience to the Web3 space.
TiltPlay combines accessible gameplay with innovative technology to deliver a seamless experience across platforms, including Telegram mini-apps and web browsers. The platform’s unique approach introduces:
- Exciting Game Variety: A growing library of casual games designed to challenge and entertain.
- Skill-Based Progression: Players are rewarded for their mastery and expertise, ensuring a fair and fun competitive environment.
- Web3 Integration: Built on Soneium, providing a decentralized and secure gaming experience.
“With TiltPlay, we’re redefining mini-games by putting fun and skill at the forefront,” said Jeffrey Huang, Product Director at TiltPlay. “Our collaboration with the Soneium ecosystem allows us to deliver a platform that’s accessible, enjoyable, and innovative for all players.”
TiltPlay is now live, inviting gamers worldwide to dive into its features, test their skills, and connect with a vibrant community.
For more information about TiltPlay, visit TiltPlay.gg.
Photo – https://mma.prnewswire.com/media/2603496/TiltPlay_launches_a_gaming_platform_Soneium.jpg
View original content:https://www.prnewswire.co.uk/news-releases/tiltplay-launches-as-a-gaming-platform-on-the-soneium-ecosystem-302357392.html
Blockchain Press Releases
Purchasers of Quantstamp QSP Tokens May Be Eligible for Payment from the Quantstamp Fair Fund
COSTA MESA, Calif., Jan. 22, 2025 /PRNewswire/ — The following statement is being issued by Simpluris, Inc., the SEC-appointed Fund Administrator.
UNITED STATES OF AMERICA
Before the
SECURITIES AND EXCHANGE COMMISSION
In the Matter of Quantstamp, Inc.
Administrative Proceeding File No. 3-21535
This Notice is Pursuant to a Distribution Plan approved by the United States Securities and
Exchange Commission in the captioned matter.
If you purchased or acquired Quantstamp QSP tokens from October 1, 2017, through July 20, 2023, inclusive, you may be eligible for a distribution from the Fair Fund created in the Securities and Exchange Commission (“SEC”) administrative proceeding captioned above (the “Fair Fund”).
The Fair Fund is being distributed pursuant to a Distribution Plan (the “Plan”) approved by the SEC. The Plan provides for the distribution of the Fair Fund to compensate investors based on their losses, due to the misconduct of Quantstamp, Inc. described in the SEC’s administrative proceeding, on the purchase of QSP tokens from October 1, 2017 through July 20, 2023. You can view and download a copy of the SEC’s order and the Plan on the Important Documents tab on the website for this matter: www.QuantstampFairFund.com/documents.
To be considered for eligibility for a Distribution Payment from the Fair Fund, you must timely submit a completed Claim Form online or via mail. Claim Forms completed online must be submitted on or before 11:59 p.m. Eastern Standard Time (“EST”) on April 10, 2025. Claim Forms submitted via mail must be sent to the address provided on the Claim Form and postmarked (or if not sent by U.S. Mail, received) by April 10, 2025.
You may complete the Claim Form online here: www.QuantstampFairFund.com/form/claim. Alternatively, you may download a paper copy from of the Claim Form on the Important Documents page www.QuantstampFairFund.com/documents, or request a copy of the paper Claim Form from the Fund Administrator via email at [email protected] or by calling 833-215-6101, for submission by mail to the address set forth on the Claim Form.
ADDITIONAL INFORMATION
Additional information regarding the Fair Fund, including copies of the Plan, the Plan Notice, the Claim Form, and other relevant documents may be found at www.QuantstampFairFund.com. You may request copies or seek additional information by contacting the Fund Administrator.
|
Email: |
|
|
Call: |
833-215-6101 |
|
Write: |
Quantstamp Fair Fund |
|
Fund Administrator |
|
|
P.O. Box 25381 |
|
|
Santa Ana, CA 92799 |
Logo – https://mma.prnewswire.com/media/1232750/New_Simpluris_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/purchasers-of-quantstamp-qsp-tokens-may-be-eligible-for-payment-from-the-quantstamp-fair-fund-302357433.html
Blockchain
Humanity Protocol Collaborates with OKX Wallet to Redefine Decentralized Identity Verification and Reward Users
The post Humanity Protocol Collaborates with OKX Wallet to Redefine Decentralized Identity Verification and Reward Users appeared first on News, Events, Advertising Options.
-
Blockchain7 days ago
Pelican AI and Christie Capital Announce Launch of Brokered Financing
-
Blockchain Press Releases6 days agoBybit: A Global Favorite Among Full-Time and Professional Traders and the World’s Second-most popular Crypto Exchange
-
Blockchain6 days ago
Sportsbet.io Becomes New Title Partner of Snooker’s Players Championship, Tour Championship and Champion of Champions
-
Blockchain Press Releases5 days agoThe Moskowitz Law Firm, PLLC Announces Preliminary Approval of a Proposed Class Action Settlement on Behalf of Purchasers of Astrals Non-Fungible Tokens and Galaxy Tokens
-
Blockchain Press Releases7 days agoBybit & SignalPlus Unveil the 100,000 USDC Global Trading Showdown
-
Blockchain5 days agoFast, Secure, and Seamless: Bybit Card QR Pay Set to Transform Payments in Brazil
-
Blockchain Press Releases6 days ago
Bybit Pledges RMB 5 Million to Support Relief Efforts Following Devastating Tibet Earthquake
-
Blockchain2 days agoCoreNest Capital Announces Strategic Investments in SpaceX, CTGT, Open Clinic, Asha Health, CollectWise, Curo, Hybrd, and Study Dojo
